ISSN: 1741-0541

Journal Home

Journal Guideline

Personalized Medicine Q3 Unclaimed

Taylor and Francis Ltd. United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Personalized Medicine is a journal indexed in SJR in Medicine (miscellaneous) and Pharmacology with an H index of 36. It has a price of 2040 €. It has an SJR impact factor of 0,412 and it has a best quartile of Q3. It has an SJR impact factor of 0,412.

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Medicine (miscellaneous) (Q3) Molecular Medicine (Q3) Pharmacology (Q3)

Price

2040 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

0,412

SJR Impact factor

36

H Index

43

Total Docs (Last Year)

146

Total Docs (3 years)

1840

Total Refs

255

Total Cites (3 years)

138

Citable Docs (3 years)

1.62

Cites/Doc (2 years)

42.79

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Swiss Medical Weekly Q3
Neurologia Q3
Canadian Journal of Experimental Psychology Q3
Journal of Physiology and Pharmacology Q3
Revista do Instituto de Medicina Tropical de Sao Paulo Q3

Compare this journals

Aims and Scope

Best articles by citations

Common polymorphisms in antioxidant genes are associated with diabetic nephropathy in Type 2 diabetes patients

Urinary proteomics: ready for prime time in urological cancer diagnostics?

Institutional Profile: USF Health: the power of creativity, the passion to improve health

National nursing workforce survey of nursing attitudes, knowledge and practice in genomics

Nonstandard personalized medicine strategies for cancer may lead to improved patient outcomes

Translating next-generation sequencing from clinical trials to clinical practice for the treatment of advanced cancers

Your DNA, Your Say': global survey gathering attitudes toward genomics: design, delivery and methods

Breath biomarkers for personalized medicine

Rising interdisciplinary collaborations refine our understanding of autisms and give hope to more personalized solutions

Research Highlights

Cytochrome P450 gene-based drug prescribing and factors impacting translation into routine clinical practice

Research Highlights

SHOW MORE ARTICLES

Ventana immunohistochemistry ALK (D5F3) detection of ALK expression in pleural effusion samples of lung adenocarcinoma

Research Highlights

Phenoconversion of CYP2C9 in epilepsy limits the predictive value of CYP2C9 genotype in optimizing valproate therapy

Realizing individualized medicine: the road to translating proteomics from the laboratory to the clinic

BACE1 levels are increased in plasma of Alzheimer's disease patients compared with matched cognitively healthy controls

Biobanking in pediatrics: the human nonsubjects approach

The Hawaii clopidogrel lawsuit: the possible effect on clinical laboratory testing

Genomics in the clinic: ethical and policy challenges in clinical next-generation sequencing programs at early adopter USA institutions

Illustrative case studies in the return of exome and genome sequencing results

Interprofessional education for personalized medicine through technology-based learning

Challenges and opportunities of pharmacogenetics in drug development

Analysis of insurance preauthorization requests forBRCA1andBRCA2genetic testing: experience of the Humana Genetic Guidance Program

Personalized Medicine Q3 Unclaimed

2040 €

NPD

0 €

Metrics

0,412

36

43

146

1840

255

138

1.62

42.79

Comments

Other journals with similar parameters

Aims and Scope

Best articles by citations

FAQS

What is the impact factor of Personalized Medicine?